Precigen, Inc. (PGEN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.10-0.56%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PGEN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -30.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
PGEN — officer change
Dated 2026-06-24
The filing is about an amendment to the company's incentive plan, not a management change.
Why it matters: Updates on PRGN-2009 will show how it is doing in treating HPV cancers. This could mean growth.
Watch forManagement will give a good update on PRGN-2009 by December 2026.
Also watch forNo update or negative news on PRGN-2009 development by December 2026.
Why it matters: Achieving cash flow break-even is a key goal for Precigen by the end of 2026.
Supportive ifManagement shares cash flow metrics. These show progress toward break-even.
Worry ifManagement says cash flow is still negative. There is no clear path to break-even.
Why it matters: Updates on cash flow are crucial to assess if the company is on track for break-even.
Supportive ifManagement says cash flow is close to break-even or has improved a lot.
Worry ifManagement says cash flow is still very negative or has gotten worse.
Why it matters: More people enrolling means PAPZIMEOS is being used more. This can lead to more revenue.
Supportive ifPatient hub enrollment surpasses 600 patients by Q3 2026.
Worry ifPatient hub enrollment remains below 500 patients by Q3 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$240 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $731 loss on $10,000 · 7.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,050 loss on $10,000 · 40.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A drop in sector revenue growth could affect Precigen's performance and outlook.
Worry ifSector revenue growth reported below its median level.
Less concerning ifSector revenue growth remains above its median level.
Why it matters: If sector revenue growth picks up, it could help Precigen's performance. It may indicate a better market environment.
Supportive ifSector revenue growth is speeding up again. It is now above 10%.
Worry ifSector revenue growth keeps slowing down. It is now below 10%.
Why it matters: Continued revenue growth from PAPZIMEOS shows strong market adoption and supports cash flow goals.
Supportive ifPAPZIMEOS revenue in Q3 exceeds $53.1 million reported in Q2.
Worry ifPAPZIMEOS revenue in Q3 falls below $53.1 million.
Why it matters: Reaching cash flow break-even is key for financial stability. It is also important for future growth.
Supportive ifManagement confirms cash flow break-even is achieved by the end of 2026.
Worry ifManagement now expects to reach cash flow break-even after 2026.
Why it matters: More enrollments show strong demand for PAPZIMEOS. This could lead to higher revenue.
Supportive ifPatient hub enrollment exceeds 500 patients by the end of Q3.
Worry ifPatient hub enrollment is still under 500 patients.
Why it matters: Updates on PRGN-2009 may show progress in HPV cancer treatments. This could affect investor confidence.
Watch forManagement gives a good update on PRGN-2009 development. They also share trial results.
Also watch forNo update is provided on PRGN-2009 development by year-end.